HOURS MAP

  • Cancer Research and Clinical Trials in Henderson, NV

    View clinical trials by diagnosis


    The Mohtaseb Cancer Center & Blood Disorders is pleased to announce that, in our continuous efforts to advance services provided at our office, we recently joined a renowned cancer and research center network. With such progress, we will have the opportunity to advance patients' care with innovative new therapeutic options in our practice. Our state-of the art facility is equipped with the latest technology, trained staff and healthcare professionals.

    Established in 2006 (First in Kingman), our practice has become a trusted name for cancer treatment and care all over Mohave County. We are dedicated to providing compassionate care and innovative cancer treatments. Our current locations in both Henderson Nevada and Bullhead City, AZ provides easy access throughout the tristate area and allows us to serve a large community in the North and West of Arizona with the highest level of care.

    At the Mohtaseb Cancer Center & Blood Disorders, we have gained extensive knowledge and experience in building successful practice over the years. We believe collaboration is crucial for the success of our mission. Our mission is to provide THE HIGHEST level of care and open the doors for all recent therapies. We are committed to a collaborative environment where our team can explore novel approaches and new treatments that can significantly impact patients global health outcomes.

    Therefore we are excited to establish a partnership with Sargon Research in Canton, OH, a leader in innovative nationwide clinical research. Nationwide, less than 3% of cancer patients are enrolled in clinical trials and only 13% of oncologists participate in clinical research. However we strongly believe that clinical trials are the future of cancer treatment and have the potential to dramatically improve patients' lives.


    What Can Clinical Research Mean for You as a Patient?

    With joining the network of clinical trials, and with our experienced team led by Dr. Mohtaseb, participating in clinical research studies will make it easier for the Mohtaseb Cancer Center & Blood Disorders to utilize more therapies and practice higher level of Hematology and Oncology. Our solutions are designed to help patients overcome any obstacles during their journey for cure and provide tailored support and guidance at every level of care.


    We are confident that by combining our expertise and resources, we can make significant strides in medical practice and improve quality of life for our patients.


    What are Clinical Trials?

    Clinical trials are research studies in which patients may volunteer to take part. We use clinical trials to find better ways to prevent, diagnose and treat cancer.

    Clinical trials are part of a long, careful process, which may take many years. First, doctors study a new treatment in the lab. Then they often study the treatment in animals. If a new treatment shows promise, doctors then test the treatment in people. Doctors do this in three to four steps, or phases.

    Are Clinical Trials Safe?

    Our most important job is to protect patients. First, we protect patients in clinical trials by following well-planned protocols:

    • Explains the treatment plan
    • Lists the medical tests patients will receive
    • Gives the number of how many patients will take part in the clinical trial
    • Lists eligibility criteria, which are guidelines to decide who may join the clinical trial
    • Explains safety information

    Second, we protect patients by using a careful informed consent process. The basic principle in clinical trials is Safety and Non-inferiority, meaning, in order to approve a clinical trial it has to be first safe, and second, not below the benefit of the current modalities available in practice.

Clinical Trials by Diagnosis

Explore the clinical trials offered through Mohtaseb Cancer Center & Blood Disorders, organized by diagnosis. Each listing includes the study name and, where available, its NCT number and a link to details on ClinicalTrials.gov.

For questions about a study, current availability, or eligibility, contact our office at (702) 361-3030.

Breast

BGB-43395-302

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

NCT number: NCT07492641

View NCT07492641 on ClinicalTrials.gov (opens in a new tab)

ROVI 289485

A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer

NCT number: NCT07340658

View NCT07340658 on ClinicalTrials.gov (opens in a new tab)

Gastric & Esophageal

BGB-A317-217

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

NCT number: NCT07554521

View NCT07554521 on ClinicalTrials.gov (opens in a new tab)

HER2+

Lung

BMS-9865545 (CA266-0002)

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

NCT number: NCT07361510

View NCT07361510 on ClinicalTrials.gov (opens in a new tab)

Pfizer C5751005

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

NCT number: NCT06758401

View NCT06758401 on ClinicalTrials.gov (opens in a new tab)

ICON 2438/0098 (STELLAR-202)

Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT number: NCT07845786

View NCT07845786 on ClinicalTrials.gov (opens in a new tab)

GSK 300599-EMBOLD

Please contact our office for the NCT number and study details.

C6461001

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT number: NCT07222566

View NCT07222566 on ClinicalTrials.gov (opens in a new tab)

Olvi-Vac-NSCLC-025

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

NCT number: NCT06463665

View NCT06463665 on ClinicalTrials.gov (opens in a new tab)

Solid Tumor

Myeloma

GKS 218670 (DREAM20)

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

NCT number: NCT05714839

View NCT05714839 on ClinicalTrials.gov (opens in a new tab)

Starton STAR-LLD-MM-023

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

NCT number: NCT06087653

View NCT06087653 on ClinicalTrials.gov (opens in a new tab)

GRIFOLS-GC2202

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

NCT number: NCT05645107

View NCT05645107 on ClinicalTrials.gov (opens in a new tab)

GSK 214828 (DREAMM10)

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

NCT number: NCT06679101

View NCT06679101 on ClinicalTrials.gov (opens in a new tab)

Back to diagnosis list